{"article_title": "Pricey hepatitis C drugs threaten health care system", "article_keywords": ["c", "pharma", "drugs", "big", "system", "hepatitis", "pricing", "pricey", "investigation", "health", "systemphoto", "threaten", "care"], "article_url": "http://www.sfchronicle.com/opinion/openforum/article/Pricey-hepatitis-C-drugs-threaten-health-care-6751291.php", "article_text": "Pricey hepatitis C drugs threaten health care system\n\nPhoto: Eric Risberg, Associated Press A bipartisan investigation by U.S. senators finds that the makers...\n\nWhen does Big Pharma profiting become profiteering? This issue was the subject last month of a Senate Finance Committee investigation of pricing practices of Gilead Sciences Inc., a leading provider of hepatitis C medications. After examining 20,000 pages of internal company documents, looking at Medicaid data and interviewing health care experts, the authors concluded that the Foster City drugmaker \u201cpursued a calculated scheme for pricing and marketing its hepatitis C drug based on one goal: maximizing revenue regardless of the human consequences.\u201d Community activists protested this kind of Big Pharma greed in front of the San Francisco hotel where the 34th annual J.P. Morgan Healthcare Conference opened Monday.", "article_metadata": {"publisher": "San Francisco Chronicle", "sailthru.image.thumb": "http://ww3.hdnux.com/photos/42/37/75/9043798/5/sailthruImage.jpg", "sailthru.author": "By Diana Sylvestre", "description": "After examining 20,000 pages of internal company documents, looking at Medicaid data and interviewing health care experts, the authors concluded that the Foster City drugmaker \u201cpursued a calculated scheme for pricing and marketing its hepatitis C drug based on one goal: maximizing revenue regardless of the human consequences.\u201d  With the hepatitis C virus affecting about 3 million people in the United States, the impact of Gilead\u2019s pricing strategy is real, measurable \u2014 and devastating.  With a 12-week course of Gilead\u2019s Harvoni priced at nearly $100,000, taxpayer-funded Medicare Part D spent $4.6 billion on hepatitis C alone in the first half of 2015, leaving seniors and disabled persons with the prospect of higher deductibles and maximum out-of-pocket costs.  Twenty-nine states said that hepatitis C was their most or second-most-costly pharmaceutical outlay, resulting in only 2.4 percent of affected Medicaid enrollees undergoing treatment.  While anticipating record profits of $30 billion in 2015, Gilead virtually eliminated its medication assistance program for all but the few Americans ineligible for coverage under the Affordable Care Act.  Drug users, incarcerated individuals and the homeless are at high risk for transmission, but a public health strategy to focus on these individuals is impossible because it is simply too expensive.  Biotechnology holds promise for an exciting wave of novel treatments for many other medical conditions, and it is the lure of profits that encourages investors to support these often risky efforts.", "vf": {"section": "opinion", "unique_id": "premiumsfgate-article-6751291"}, "author.name": "By Diana Sylvestre", "og": {"site_name": "San Francisco Chronicle", "description": "After examining 20,000 pages of internal company documents, looking at Medicaid data and interviewing health care experts, the authors concluded that the Foster City drugmaker \u201cpursued a calculated scheme for pricing and marketing its hepatitis C drug based on one goal: maximizing revenue regardless of the human consequences.\u201d  With the hepatitis C virus affecting about 3 million people in the United States, the impact of Gilead\u2019s pricing strategy is real, measurable \u2014 and devastating.  With a 12-week course of Gilead\u2019s Harvoni priced at nearly $100,000, taxpayer-funded Medicare Part D spent $4.6 billion on hepatitis C alone in the first half of 2015, leaving seniors and disabled persons with the prospect of higher deductibles and maximum out-of-pocket costs.  Twenty-nine states said that hepatitis C was their most or second-most-costly pharmaceutical outlay, resulting in only 2.4 percent of affected Medicaid enrollees undergoing treatment.  While anticipating record profits of $30 billion in 2015, Gilead virtually eliminated its medication assistance program for all but the few Americans ineligible for coverage under the Affordable Care Act.  Drug users, incarcerated individuals and the homeless are at high risk for transmission, but a public health strategy to focus on these individuals is impossible because it is simply too expensive.  Biotechnology holds promise for an exciting wave of novel treatments for many other medical conditions, and it is the lure of profits that encourages investors to support these often risky efforts.", "title": "Pricey hepatitis C drugs threaten health care system", "url": "http://www.sfchronicle.com/opinion/openforum/article/Pricey-hepatitis-C-drugs-threaten-health-care-6751291.php", "image": "http://ww3.hdnux.com/photos/42/37/75/9043798/5/rawImage.jpg", "locality": "San Francisco", "longitude": "-122.41941550000001", "street-address": "San Francisco, CA, USA", "latitude": "37.7749295", "type": "article", "region": "California", "country-name": "United States"}, "twitter": {"site": "@sfchronicle", "card": "summary_large_image"}, "sailthru.date": "2016-01-11 15:05:00 -0800", "sailthru.title": "Pricey hepatitis C drugs threaten health care system", "date.release": "2016/11/01", "fb": {"admins": 100006394927810, "app_id": 537896802938133}, "sailthru.location": "37.7749295, -122.41941550000001", "time.release": "15:05", "ICBM": "37.7749295, -122.41941550000001", "msvalidate.01": "9451CA04ABC9D1D5C6419C73B4C4F7B7", "news_keywords": "prescription drugs,cancer,pharmaceutical", "sailthru.tags": "section-opinion,column-open-forum,subject-drugs,subject-medicaid,subject-drug-prices,pubname-san-francisco-chronicle,hepatitis,health-care,health-care-system,treatment,pricey-hepatitis,conscientious-drug-pricing,medication-assistance-program,pricing-practices,pricing,drug-prices,medication,pricing-transparency,pharmaceutical-innovation-holds,pricing-strategy,insurers,pricing-levels,isPremium", "sections": "Opinion,Open Forum", "viewport": "initial-scale = 1.0, maximum-scale = 1.0, width = device-width", "subject": "prescription drugs,cancer,pharmaceutical"}, "article_summary": "Pricey hepatitis C drugs threaten health care systemPhoto: Eric Risberg, Associated Press A bipartisan investigation by U.S. senators finds that the makers...\nThis issue was the subject last month of a Senate Finance Committee investigation of pricing practices of Gilead Sciences Inc., a leading provider of hepatitis C medications.\nWhen does Big Pharma profiting become profiteering?\nAfter examining 20,000 pages of internal company documents, looking at Medicaid data and interviewing health care experts, the authors concluded that the Foster City drugmaker \u201cpursued a calculated scheme for pricing and marketing its hepatitis C drug based on one goal: maximizing revenue regardless of the human consequences.\u201d Community activists protested this kind of Big Pharma greed in front of the San Francisco hotel where the 34th annual J.P. Morgan Healthcare Conference opened Monday."}